278 related articles for article (PubMed ID: 34553814)
1. The effectiveness and safety of low dose trimethoprim-sulfamethoxazole for the treatment of pneumocystis pneumonia: A systematic review and meta-analysis.
Tritle BJ; Hejazi AA; Timbrook TT
Transpl Infect Dis; 2021 Dec; 23(6):e13737. PubMed ID: 34553814
[TBL] [Abstract][Full Text] [Related]
2. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study.
Chen RY; Li DW; Wang JY; Zhuang SY; Wu HY; Wu JJ; Qu JW; Sun N; Zhong C; Zhu C; Zhang M; Yu YT; Yuan XD
Int J Infect Dis; 2022 Dec; 125():209-215. PubMed ID: 36243280
[TBL] [Abstract][Full Text] [Related]
5. A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.
Li H; Lu Y; Tian G; Wu Y; Chen T; Zhang J; Hu N; Wang X; Wang Y; Gao L; Yan J; Zhou L; Shi Q
BMC Infect Dis; 2024 Jan; 24(1):152. PubMed ID: 38297200
[TBL] [Abstract][Full Text] [Related]
6. Low-Dose TMP-SMX in the Treatment of
Butler-Laporte G; Smyth E; Amar-Zifkin A; Cheng MP; McDonald EG; Lee TC
Open Forum Infect Dis; 2020 May; 7(5):ofaa112. PubMed ID: 32391402
[TBL] [Abstract][Full Text] [Related]
7. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
Awad M; Sierra CM; Mesghali E; Bahjri K
J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
[TBL] [Abstract][Full Text] [Related]
8. Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality.
Song S; Zhang Y; Yu J; Xie C; Chen Y; Zhang X
BMC Infect Dis; 2022 Dec; 22(1):961. PubMed ID: 36575406
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV: A Multicenter, Retrospective Observational Cohort Study.
Nagai T; Matsui H; Fujioka H; Homma Y; Otsuki A; Ito H; Ohmura S; Miyamoto T; Shichi D; Tomohisa W; Otsuka Y; Nakashima K
Chest; 2024 Jan; 165(1):58-67. PubMed ID: 37574166
[TBL] [Abstract][Full Text] [Related]
10. Pneumocystis jirovecii Pneumonia in a Liver Transplant Recipient With an Adverse Reaction to Trimethoprim/Sulfamethoxazole Treated With a Sulfonamide Desensitization Protocol: Case Report.
Baran K; Furmańczyk-Zawiska A; Wieczorek-Godlewska R; Nitek P; Durlik M
Transplant Proc; 2024 May; 56(4):1000-1005. PubMed ID: 38760300
[TBL] [Abstract][Full Text] [Related]
11. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.
Utsunomiya M; Dobashi H; Odani T; Saito K; Yokogawa N; Nagasaka K; Takenaka K; Soejima M; Sugihara T; Hagiyama H; Hirata S; Matsui K; Nonomura Y; Kondo M; Suzuki F; Tomita M; Kihara M; Yokoyama W; Hirano F; Yamazaki H; Sakai R; Nanki T; Koike R; Kohsaka H; Miyasaka N; Harigai M
Arthritis Res Ther; 2017 Jan; 19(1):7. PubMed ID: 28100282
[TBL] [Abstract][Full Text] [Related]
12. Low-dose trimethoprim-sulfamethoxazole for the treatment of
Sohani ZN; Butler-Laporte G; Aw A; Belga S; Benedetti A; Carignan A; Cheng MP; Coburn B; Costiniuk CT; Ezer N; Gregson D; Johnson A; Khwaja K; Lawandi A; Leung V; Lother S; MacFadden D; McGuinty M; Parkes L; Qureshi S; Roy V; Rush B; Schwartz I; So M; Somayaji R; Tan D; Trinh E; Lee TC; McDonald EG
BMJ Open; 2022 Jul; 12(7):e053039. PubMed ID: 35863836
[TBL] [Abstract][Full Text] [Related]
13. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of effectiveness, hyperkalaemia, and hepatotoxicity of trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis jirovecii pneumonia in paediatric patients: A single-centre retrospective study.
Kato H; Hagihara M; Asai N; Mikamo H; Iwamoto T
Int J Antimicrob Agents; 2024 May; 63(5):107151. PubMed ID: 38508538
[TBL] [Abstract][Full Text] [Related]
15. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.
Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787
[TBL] [Abstract][Full Text] [Related]
16. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study.
Geerlinks AV; Campigotto A; Science M; Gupta S
Eur J Cancer; 2020 Nov; 140():71-75. PubMed ID: 33059195
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
[TBL] [Abstract][Full Text] [Related]
18. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
Singh R; Bemelman FJ; Hodiamont CJ; Idu MM; Ten Berge IJ; Geerlings SE
BMC Infect Dis; 2016 Feb; 16():90. PubMed ID: 26912326
[TBL] [Abstract][Full Text] [Related]
19. Impact of an intravenous trimethoprim/sulfamethoxazole shortage on treatment outcomes among HIV-infected patients with Pneumocystis jirovecii pneumonia.
Dilworth TJ; Ibrahim OM; Mercier RC
J Manag Care Spec Pharm; 2014 Dec; 20(12):1246-54. PubMed ID: 25443518
[TBL] [Abstract][Full Text] [Related]
20. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study.
Nakashima K; Aoshima M; Nakashita T; Hara M; Otsuki A; Noma S; Misawa M; Otsuka Y; Motojima S
J Microbiol Immunol Infect; 2018 Dec; 51(6):810-820. PubMed ID: 28779879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
